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Abstract  
 
Background: Significant subset of prostate cancer (PC) patients with castration-resistant form of the 
disease (CRPC) show primary resistance to androgen receptor (AR)-targeting drugs developed against 
CRPC. As one explanation could be the expression of constitutively active androgen receptor splice 
variants (AR-Vs), our current objectives were to study AR-Vs and other AR aberrations to better 
understand the emergence of CRPC. Methods: We analyzed specimens from different stages of prostate 
cancer by next-generation sequencing and immunohistochemistry. Results: AR mutations and copy 
number variations were detected only in CRPC specimens. Genomic structural rearrangements of AR 
were observed in 5/30 metastatic CRPC patients but they were not associated with expression of 
previously known AR-Vs. The predominant AR-Vs detected were AR-V3, AR-V7 and AR-V9, with the 
expression levels being significantly higher in CRPC cases compared to prostatectomy samples. Out of 
25 CRPC metastases that expressed any AR variant, 17 cases harbored expression of all three of these 
AR-Vs. AR-V7 protein expression was highly heterogeneous and higher in CRPC compared to hormone-
naïve tumors. Conclusions: AR-V3, AR-V7 and AR-V9 are co-expressed in CRPC metastases 
highlighting the fact that inhibiting AR function via regions common to all AR-Vs is likely to provide 
additional benefit to patients with CRPC. 
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Introduction 
 
Prostate cancer (PC) is the most common malignancy and third most common cause of cancer-related 
death among men in Europe. Androgens are required for the normal development of prostate tissue and 
exert their effects through androgen receptor (AR) mediated signaling but also have important role during 
prostate cancer emergence and progression. Most prostate cancers grow slowly and are curable by 
surgery and radiation when confined to the prostate. In contrast, treatment of prostate cancers that have 
spread outside the prostate usually includes manipulation of the AR signaling axis; androgen deprivation 
therapy (ADT) either by surgical or chemical castration. However, during currently available ADT, lethal 
castration-resistant form of prostate cancer (CRPC) will eventually emerge after a variable period of 
time. Even though the exact mechanism by which CRPC develops remains to be fully understood, several 
mechanisms of castration resistance have been identified such as AR gene amplification1,2, point 
mutations in AR gene3,4 and induction of steroidogenesis in CRPC cells5-7. AR gene amplification has 
been demonstrated in approximately 30% of CRPCs1. Cancers with AR amplification have been shown 
to respond better to second-line maximal androgen blockade compared to tumors without the 
amplification, however, the response was short-lived8. Also AR mutations are rare even at CRPC stage 
being present in approximately 10–30% of cases4. These mutations are almost always associated with 
diverse gains-of-function and about 45% of the mutations occur in the ligand-binding domain9. AR 
mutations can broaden ligand specificity to alternative steroid hormones, hypersensitize the receptor to 
castrate levels of androgens or lead to resistance to current forms of treatment making AR active even in 
the presence of anti-androgens10.  
 
Importantly, androgen signaling remains active even in the CRPC stage11,12. The established concept of 
sustained AR signaling during CRPC has led to the clinical development of second-generation AR-
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targeting drugs enzalutamide and abiraterone that target the ligand-binding domain of AR directly and 
indirectly, respectively. Enzalutamide is an AR antagonist whereas abiraterone is a CYP17 inhibitor 
approved by the US Food and Drug Administration (FDA) for the treatment of metastatic CRPC. Several 
studies have shown that presence of AR amplification or AR mutations in plasma samples is associated 
with worse outcome with enzalutamide and abiraterone13-17. Furthermore, a significant subset of patients 
show primary resistance to these agents with respect to PSA (prostate-specific antigen) level18 and among 
patients who initially respond, nearly all eventually develop acquired resistance. 
 
One potential explanation for the resistance to first- and second-generation AR-targeted therapies is the 
presence of AR splice variants (AR-Vs). AR-Vs are alternatively spliced isoforms of the AR mRNA 
usually resulting in truncated AR protein product. The key domains shared among wild-type full-length 
AR (AR-FL) and all AR-Vs are the NH2-terminal transactivating domain (NTD) and DNA-binding 
domain (DBD). However, AR-Vs lack variable portions of the COOH-terminal domain including the 
ligand-binding domain (LBD)19-21. In spite of the fact that AR-Vs are unable to bind a ligand, they are 
constitutively active as transcription factors and capable of activating target genes22. 
 
To date, at least 22 AR-Vs have been discovered in CRPC specimens23. AR-V7 is the most clinically 
relevant variant as it is most frequently observed and the most abundant AR-V in clinical specimens. In 
addition, AR-V7 is the only variant that can be detected reproducibly at both the mRNA and protein 
levels. Moreover, detection of AR-V7 mRNA in circulating tumor cells (CTCs) and peripheral whole 
blood from CRPC patients treated with enzalutamide or abiraterone has been implicated in primary 
resistance and shorter progression-free and overall survival24-27. Interestingly, the prevalence of AR-V7 
was shown to be higher in enzalutamide-treated men who had previously received abiraterone and in 
abiraterone-treated men who had previously received enzalutamide25. These findings were supported by 
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an independent study that also utilized CTC-based RT-PCR assay28. In this prospective study, it was 
shown that PSA response rate to abiraterone or enzalutamide was 7% among AR-V7 positive patients and 
63% among AR-V7 negative patients. Another recent study demonstrated that AR-V7 detection in plasma-
derived exosomal RNA strongly predicts resistance to enzalutamide or abiraterone in CRPC patients29. 
Although these studies implicate that AR-V7 could be used as a treatment-specific biomarker, it is likely 
that other AR-Vs also play a role in the development of CRPC. For example, it was recently reported 
that AR-V9 is often co-expressed with AR-V7 in CRPC metastases and predicts primary resistance to 
abiraterone30.  
 
Recently, genomic structural rearrangements of AR (AR-GSRs) were established as a new class of AR 
gene alteration occurring in one third of CRPC-stage specimens31. This work showed that the presence 
of AR-GSRs at high variant allele frequency was associated with outlier, tumor-specific expression of 
rearrangement-dependent AR-V species that displayed androgen-independent and enzalutamide-resistant 
transcriptional activity. However, contrary to the prior studies in cell lines32,33, AR-GSRs were not 
associated with the AR-V7 expression levels in metastatic CRPC tissue31. Another recent study utilizing 
peripheral blood collected from patients with CRPC detected intra-AR structural variation in 15/30 
patients of whom 14 expressed AR-Vs34. Of note, most of the AR-V positive patients expressed multiple 
AR-Vs with AR-V7 being the most frequently occurring splice variant. However, AR-V3 was the most 
abundantly expressed AR splice variant. According to this study the presence of any AR-V was associated 
with shorter progression-free survival after second-line endocrine treatment compared to patients that 
did not harbor AR-Vs34. Furthermore, in another recent investigation AR-GSRs in circulating tumor DNA 
were shown to associate with primary resistance to enzalutamide or abiraterone also in treatment-naïve 
CRPC patients with metastatic disease13.   
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Our aim was to study AR splice variants, rearrangements, mutations and copy number variations (CNVs) 
in different stages of prostate cancer to better understand the emergence of CRPC. We used multiple 
sample cohorts representing hormone-naïve prostate cancers and lymph node metastases as well as 
locally recurrent and metastatic CRPCs. We first employed whole genome and whole transcriptome 
sequencing followed by targeted AR sequencing panels allowing deeper sequence coverage. In particular, 
our aim was to confirm whether AR-Vs are expressed in higher levels in CRPC samples compared to 
earlier stage cancers. In addition, we wished to elucidate to which extent AR-V expression is due to the 
aberrant splicing and, on the other hand, AR gene rearrangements. We also wanted to study the 
association between AR-V and AR-FL expression and to find out whether AR-V expression affects the 
expression of AR-regulated genes.  
 
Materials and methods 
 
Sample sets 
 
Two different sample sets utilized in the study are shown in Table 1 and are described in more detail in 
Supplementary Table S1. The sample set 1 contained freshly frozen tissue specimens from benign 
prostatic hyperplasia (BPH) (n=12), hormone-naïve prostate cancer (n=30) and locally recurrent CRPC 
(n=13) with clinicopathological characteristics of prostate cancer cases and prior treatments of CRPC 
cases being shown in Supplementary Table S1. BPH samples were obtained by radical prostatectomy, 
cystoprostatectomy and by transurethral resection of the prostate. Hormone-naïve prostate cancer 
samples were obtained by radical prostatectomy and locally recurrent CRPCs by transurethral resection 
of the prostate. Histological evaluation and Gleason grading were performed by a pathologist based on 
hematoxylin/eosin stained slides. All samples contained a minimum of 70% cancerous or hyperplastic 
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cells. DNA and RNA were isolated simultaneously using an AllPrep DNA/RNA Mini Kit (Qiagen, 
Valencia, CA, USA) according to manufacturer’s protocol. For certain samples, additional total RNA 
was isolated using Trizol (Invitrogen, Carlsbad, CA, USA) extraction according to manufacturer’s 
protocol. Three CRPC samples had RNA extracted using both Trizol and Qiagen AllPrep. Integrity was 
checked using Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).  
 
The sample set 2 consisted of 24 additional hormone-naïve prostate cancers removed by prostatectomy 
of which six specimens were also included in sample set 1, eight lymph node metastases obtained at 
lymphadenectomy and 30 metastatic CRPC specimens obtained at autopsy (clinicopathological 
characteristics of the cases are shown in Supplementary Table S1). Hormone-naïve prostate cancer 
samples contained a minimum of 60% cancerous or hyperplastic cells and were processed as described 
in the previous section. 
 
Portions of the metastatic cancer tissue from pelvic lymphatic metastasis obtained at lymphadenectomy 
were used for this study. None of the eight patients had undergone androgen deprivation therapy, 
chemotherapy, or radiation therapy prior to this surgery. Precise histological control was achieved for all 
tissues studied in this group using the following protocol. Serial cryostat sectioning was used to identify 
portions of the sample containing a lower fraction of tumor cells. These areas were manually 
microdissected from the tissue block every 300 µm based on H&E stained slide visual analysis. The 
tumor cell fraction was 70% or greater by histologic visual estimation. DNA purification was performed 
as described previously35. Total RNA was isolated using an AllPrep DNA/RNA/miRNA Universal Kit 
(Qiagen, Valencia, CA, USA) according to manufacturer’s instructions. The integrity of isolated RNA 
was confirmed using Fragment Analyzer (Advanced Analytical Technologies, Ankeny, IA, USA).  
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Metastatic CRPC specimens were obtained from 30 men who participated in the PELICAN (Project to 
ELIminate lethal CANcer) integrated clinical-molecular autopsy study of metastatic prostate cancer (a 
detailed sample list is shown in Supplementary Table S1). Androgen axis and corticosteroid clinical 
treatments are listed in the Supplementary Table S1. All metastases (one metastasis per patient) and 
noncancerous (normal, NL) control samples studied were obtained at autopsy. Isolated frozen tissue 
samples were serial cryostat microdissected for histological tumour purity >75%, and high-molecular-
weight DNA was isolated using proteinase K digestion and phenol/chloroform extraction. Total RNA 
was isolated using an AllPrep DNA/RNA/miRNA Universal Kit (Qiagen, Valencia, CA, USA) according 
to manufacturer’s instructions. The integrity of isolated RNA was confirmed using Fragment Analyzer 
(Advanced Analytical Technologies, Ankeny, IA, USA).  
 
Low-coverage (4–6x) whole genome DNA sequencing and whole transcriptome sequencing (applied to 
sample set 1) have been described before36. 
 
Targeted AR DNA assay library construction and sequencing (applied to sample set 2) 
 
A custom DNA sequencing panel was designed to cover all AR exons and introns. In addition, FOXA1 
exons and SPOP exons 6–7 were included in the panel. Targeted sequence enrichment was performed 
using the SureSelectXT Target Enrichment System (Agilent Technologies, Santa Clara, CA, USA) 
according to manufacturer’s instructions. Briefly, 200 ng of genomic DNA was fragmented using 
Covaris® (Covaris, MA, USA) to yield a fragment size of 150–200 bp. End repair, addition of the 3’-dA 
overhang, ligation of indexing-specific adaptors, hybridization to custom RNA baits, hybrid capture 
selection and index tagging were performed according to the Illumina paired-end sequencing library 
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protocol. All recommended quality controls were performed between steps. The multiplexed samples 
were sequenced on the Illumina Miseq platform using 150 bp paired-end reads. 
 
Targeted AR RNA assay library construction and sequencing (applied to sample set 2) 
 
AR and five androgen-responsive genes (KLK3, FKBP5, TMPRSS2, ACPP and SLC45A3) were targeted 
for capture and sequencing. In addition, three house-keeping genes TBP, STARD7 and DDX1 were 
included for normalization purposes. This custom RNA sequencing panel was designed to cover all AR 
exons and nonrepetitive intronic regions to enable investigation of most common AR splicing variants 
(AR-V3, AR-V4, AR-V5, AR-V6, AR-V7, AR-V9, AR-V12 and AR-45); other genes were covered less 
intensively (1 or 5 amplicons per gene). Targeted sequence enrichment was performed using the 
SureSelectXT RNA Target Enrichment System (Agilent Technologies, Santa Clara, CA, USA) according 
to manufacturer’s instructions. Briefly, poly(A) RNA was purified from 1 µg of total RNA and 
fragmented chemically. In the following steps, samples were prepared using SureSelect Strand-Specific 
RNA Library Prep Kit to obtain adaptor-ligated cDNA library amplicons. Finally, hybridization to 
custom RNA baits, hybrid capture selection and index tagging were performed. All the AMPure XP bead 
purification steps were conducted as instructed. The multiplexed samples were sequenced on the Illumina 
Miseq platform using 150 bp paired-end reads. The following modifications were made to the protocol 
if RNA was highly degraded (RQN < 6 determined by Fragment Analyzer) as recommended by Agilent 
Technologies: 1) Instead of poly(A) RNA purification from 1 µg total RNA, Ribo-Zero Gold Magnetic 
Kit (Illumina, San Diego, CA, USA) was used to remove rRNA from 2 µg of total RNA. 2) Instead of 
fragmenting the purified RNA at 94ºC for 8 min, RNA was denatured at 65ºC for 5 min. 3) All AMPure 
XP bead purification steps were performed using 1.8:1 bead volume to sample volume ratio. 4) Instead 
of 13 cycles in the pre-capture PCR, the number of cycles was increased to 14.  
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Validation of the targeted sequencing panels 
 
Targeted custom SureSelect sequencing panels were validated by evaluating their performance in 
detecting AR aberrations in comparison to our previously published whole genome DNA-seq data37,38 
and whole transcriptome RNA-seq data from this study. There was a good concordance in mutation 
detection between SureSelect DNA panel and previously analyzed data from 22Rv1 cell line sample and 
metastatic CRPC samples from patients A21, A22 and A24. SureSelect DNA-seq detected the previously 
found H875Y mutation from 22Rv1 cell line, L702H mutation from liver metastasis from patient A21 as 
well as T878A mutation from a pelvic lymph node metastasis from patient A22 and from a right rib 
metastasis from patient A2437,38. The data from AR splicing variant analysis also showed good 
accordance between SureSelect RNA panel and whole transcriptome RNA-seq in three prostate cancer 
cell lines and two patient samples (Supplementary Fig. S1). It should be noted that SureSelect RNA assay 
was more sensitive in detecting AR-V9 than whole transcriptome RNA-seq.  
 
Bioinformatics 
 
For analysis of targeted DNA-seq data, Illumina MiSeq reads were aligned to GRCh37 (hg19) genome 
using Bowtie239. AR, FOXA1 and SPOP variants were called using an in-house pipeline that utilizes 
samtools mpileup40. Filtered variants were annotated using the ANNOVAR software41. Variants in 
dataset 1 were analyzed from the whole transcriptome sequencing data similarly. 
 
AR copy numbers were analyzed by calculating aligned read counts within overlapping 400 bp windows 
along the targeted regions using bedtools42. The median of all AR bait coverage ratios that were obtained 
by dividing each normalized bait coverage value by the median of all values, was used as the estimate of 
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AR copy number. Chromosomal rearrangements were called using the in-house Breakfast algorithm that 
looks for paired-end reads and individual mates overlapping a chromosomal breakpoint. 
 
For AR splice variant analysis using targeted or WTS RNA-seq data, Illumina MiSeq reads or HiSeq 
reads were aligned to an indexed reference fasta file containing unique signature sequences for various 
AR-Vs and AR-FL. The signatures consisted of 130 bp of the 3’ end of upstream exon and 130 bp of the 
5’ end of downstream exon of a given unique splice junction (Supplementary Table S2). Relative AR-V 
expression was estimated as the percentage of all AR transcripts by dividing the number of reads aligned 
to a given AR-V signature by the total number of reads aligning to all the splice junctions containing the 
same upstream exon. 
 
Expression levels of known AR-regulated genes were determined by aligning RNA-seq reads to GRCh37 
genome using TopHat243. Z-scores were calculated from the normalized read counts, and AR-signaling 
score was computed as the sum of the Z-scores of all AR-regulated genes. Full bioinformatics methods 
are described in the Supplementary methods.  
 
Immunohistochemistry 
 
Formalin-fixed, paraffin-embedded tumor microarrays of hormone-naïve PC, locally recurrent CRPC 
and metastatic CRPC (described in Leinonen et al. 2013) were used. Immunohistochemistry for AR (with 
N-terminal antibody recognizing full length AR and the variants) has been previously described44. For 
AR-V7-specific staining, sections were deparaffinized and antigen retrieval was performed by using Tris-
EDTA buffer 0.05% Tween-20 (pH 9) at +98°C for 15 minutes. The staining was performed by Lab 
Vision Autostainer (ThermoFischer Scientific Inc., Waltham, MA, USA). The primary antibody Anti-
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Androgen Receptor (AR-V7 specific) Rabbit Monoclonal Antibody [RM7] (RevMAb Biosciences, San 
Francisco, CA, USA) and secondary antibody (N-Histofine® Simple Stain MAX PO; Nichirei, Tokyo, 
Japan) were used. ImmPACT DAB (Vector Laboratories, Burlingame, CA, USA) was used as a 
chromogen. The sections were counterstained with hematoxylin and mounted with DPX mounting 
medium (Sigma-Aldrich). The percentage of AR-V7 positive cells between PC and CRPC groups was 
statistically assessed with Mann-Whitney test. 
 
Results  
 
AR mutations and CNVs are detected only in CRPC cases 
 
Since the mechanisms leading to emergence of CRPC are still largely unknown, we wanted to study the 
expression of AR splicing variants and other AR aberrations in tandem during different stages of prostate 
cancer. For this purpose, we performed low-coverage whole genome DNA sequencing and whole 
transcriptome sequencing in sample set 1 that included BPH specimens, hormone-naïve prostate cancer 
from prostatectomies and locally recurrent CRPCs (Supplementary Fig. S2). In addition, we performed 
targeted AR DNA and RNA sequencing in sample set 2 that contained hormone-naïve prostate cancer 
from prostatectomies and lymph node metastases as well as CRPC metastases (Fig. 1).  
 
First, we wanted to analyze the status of AR mutations and CNVs across widely diverse set of samples 
to better understand their potential link to AR-V expression. As expected, AR mutations and CNVs were 
detected only in locally recurrent and metastatic CRPC specimens (Fig. 1 and Supplementary Fig. S2, 
upper panels). T878A mutation that has been shown to confer agonist activity of flutamide on the AR45-
47 was found in 1/13 (8%) of locally recurrent CRPC specimens and in 2/23 (9%) of metastatic CRPC 
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specimens. L702H mutation that converts glucocorticoids to AR agonists48,49 was found in 3/23 (13%) 
of metastatic CRPC specimens. Indeed, all three patients harboring L702H mutation had been treated 
with glucocorticoids (Supplementary Table S1; a detailed treatment history is shown for patients having 
AR mutations). Copy number gains (>1 copy of AR) or amplifications (>2 AR copies) were observed in 
4/9 (44%) of locally recurrent CRPC specimens and in 19/23 (83%) of metastatic CRPC specimens, 
respectively (Fig. 1 and Supplementary Fig. S2). It should be noted that there were striking differences 
in AR copy numbers in metastatic CRPC specimens; for example, the lesion from patient A7 had six AR 
copies whereas the lesion from patient A4 had as many as 68 AR copies. In four metastatic CRPC 
specimens, AR gain or amplification co-occurred with AR mutation. Since a large body of data, including 
our current investigation, has established that there are no mutations or copy number aberrations of AR 
in untreated prostate cancers, majority of prostatectomy specimens in sample set 2 were not assayed with 
the targeted SureSelect DNA panel (Fig. 1). Additionally, data from targeted DNA assay is missing from 
those metastatic CRPC specimens of which DNA was not available (Fig. 1). The overall average 
coverage of the targeted regions in the samples ranged from 109X to 1829X, with the average coverage 
in the AR region being somewhat higher (114X–3358X). 
 
The expression of AR-Vs is highest in CRPCs and associates with expression of AR-FL 
 
Next we studied the presence of known AR-Vs that were detected from the RNA-seq data by aligning the 
reads against indexed AR-V signature sequence file containing exon-exon junction sequences unique to 
every AR-V under investigation (an example of RNA-seq read alignment of patient A17 is visualized in 
Supplementary Fig. S3). The AR-Vs detected by our assays included AR-V3, AR-V4, AR-V5, AR-V6, AR-
V7 and AR-V9. The expression levels of AR-V4, AR-V5 and AR-V6 were negligible in comparison to AR-
V3, AR-V7 and AR-V9, and were mainly observed in CRPC metastases. In sample set 1 run by whole 
15 
 
transcriptome RNA-seq, BPH specimens were mainly devoid of AR-V expression. Instead, AR-V3 and 
AR-V7 expression were detected in both hormone-naïve prostate cancer from prostatectomies and locally 
recurrent CRPCs with minimal co-expression of AR-V9 (Supplementary Fig. S2). Whereas the 
expression of AR-V3 was quite similar in the two different categories of samples, higher AR-V7 
expression levels were detected in locally recurrent CRPCs as compared with hormone-naïve prostate 
cancer from prostatectomies. Since the depth of the whole transcriptome sequencing was not satisfactory 
(average per-base sequence coverage ranged from 14X–137X) in terms of reliable detection of AR 
variants, we also performed targeted RNA sequencing of the AR which provided an average coverage 
range from 95X to 2247X utilizing sample set 2 (Fig. 1). In sample set 2, the expression level of AR-V7 
but also levels of AR-V3 and AR-V9 were higher in metastatic lesions from CRPC cases compared to 
hormone-naïve prostate cancer from prostatectomy (Fig. 1). The differences were statistically significant 
for either variant alone (Supplementary Table S3) or when their expression fractions were combined 
(p=0.0006, unpaired Wilcoxon rank sum test, Table 2). In addition, metastatic CRPC cases expressed 
significantly more AR-V3, AR-V7 and AR-V9 compared to non-androgen deprived pelvic lymph node 
metastases (p=0.0282, unpaired Wilcoxon rank sum test, Table 2). We also studied whether the 
expression of AR-Vs is associated with the CNV status (neutral vs. duplicated/amplified AR) in sample 
set 2. There was a modest correlation when CNV status was compared to the combined expression levels 
of AR-V3, AR-V7 and AR-V9 (rho=0.39, p=0.005, Spearman’s rank correlation).   
 
In sample set 2, AR-FL expression was three-fold higher in metastatic CRPC compared to hormone-naïve 
prostate cancer from prostatectomy specimens whereas in sample set 1, AR-FL was expressed five-fold 
higher in CRPC lesions than in prostatectomy samples. Notably, the expression of AR-V3, AR-V7, and 
AR-V9 was strongly associated with the levels of full-length AR in sample set 2 (Fig. 2) and in sample 
set 1 (Supplementary Fig. S4) suggesting that the expression of AR locus drives the expression of AR-Vs 
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both in hormone-naïve prostate cancer and in CRPC. Furthermore, there was strong and highly 
significant correlation between the expression of each individual AR-V compared to other AR-Vs in 
sample set 2 (Fig. 3). 
 
We also asked whether AR variant expression affects the expression of AR-regulated genes. This was 
done by calculating the summed z-score of five androgen responsive genes (KLK3, FKBP5, TMPRSS2, 
ACPP and SLC45A3) (Fig. 1, Supplementary Fig. S2). AR-V expression was not associated with AR-
regulated gene expression in sample set 2 when the proportion of fractions, when compared to AR-FL, 
of each AR-V or all AR-Vs combined, were plotted against AR signaling score (Supplementary Fig. S5). 
In addition, we wanted to test whether AR-V3, AR-V7 or AR-V9 expression correlates in particular to 
KLK3 expression. No correlation between either variant and KLK3 was detected in metastatic CRPC 
specimens (Supplementary Fig. S6). We next studied mutation status of two AR-regulating genes, 
FOXA1 and SPOP, in sample set 2. FOXA1 mutations were found in 3/8 (38%) lymph node metastases 
and in 1/23 (4%) CRPC metastases whereas SPOP mutations were detected in 1/8 (13%) lymph node 
metastases and in 2/23 (9%) CRPC metastases (Fig. 1). We did not find any association between FOXA1 
or SPOP mutation status and AR-regulated gene expression. All mutations found in this study and their 
variant allele frequencies are shown in Supplementary Table S4. 
 
AR genomic structural rearrangements occur in the context of amplified AR 
 
AR genomic structural rearrangements (AR-GSRs) were recently identified as a novel class of AR 
alteration using both autopsy CRPC specimens and peripheral blood collected from CRPC patients31,34. 
More importantly, the presence of AR-GSRs was associated with expression of AR-Vs in both studies. 
To this end, we analyzed AR DNA-seq data with our structural variant detection pipeline to identify AR-
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GSRs, defined as events having at least one breakpoint detected within the AR gene region. Average per-
base sequence coverage of the AR gene region ranged from 114X–3358X and on average 78% of AR was 
covered by at least 10 reads (range 76%–82%). We detected putative AR-GSRs in 5/30 metastatic CRPC 
patients who all harbored a highly amplified AR (Supplementary Table S5). All other sample types were 
negative for AR-GSRs when cut-off of 10 supporting split reads was used. It should be noted that none 
of the AR-GSRs occurred along with AR missense mutations. The break fusion junctions of AR-GSRs 
were variable demonstrating several types of rearrangements including duplication, deletion, inversion 
and translocation events. Furthermore, all patients demonstrated unique AR-GSR breakpoint locations. 
Interestingly, Patient A27 displayed a rearrangement that deleted half of exon 4 as well as exons 5 and 6 
and was the only patient whose AR-GSR was also detected from the RNA-seq sample (Supplementary 
Fig. S7). This rearrangement may lead to translation of a truncated, constitutively active protein product 
and could thus have some biological relevance. None of the AR-GSRs detected by our pipeline were 
associated with the expression of previously known AR-Vs and their variant allele fractions were 
relatively low (range 2.6–10.9%).  
 
Expression of AR-V7 is heterogeneous at the protein level 
 
To study how the detected differences in AR variant expression between prostate cancer stages are 
translated to the protein level, we performed immunohistochemistry against AR-V7 with tumor 
microarrays of hormone-naïve PC from prostatectomies (n=146), locally recurrent CRPCs (n=97), and 
metastatic CRPC samples (103 metastases in total from 31 patients; 1-5 metastases per patient). We also 
studied immunohistochemistry of AR (N-terminal antibody recognizing full length AR as well as all 
variants containing exon 1, including AR-V3, AR-V7 and AR-V9). As a positive control we used a sample 
of 22Rv1 cell line known to contain high AR-V7 expression (Supplementary Fig. S8a). Primarily, AR-
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V7 was detected in the nucleus (92% of hormone-naïve, 62% of CRPC and 75% of metastatic samples), 
although variable cytoplasmic staining could be detected in minority of the samples in all phases of the 
disease (12% of hormone-naïve, 32% of CRPC and 21% of metastatic samples) (Supplementary Fig. 
S8b). In contrast to AR staining, the AR-V7 staining was heterogeneous and often present in only a 
fraction of the cells (Supplementary Fig. S8b). For example, 89% of the positive, hormone-naïve cases 
had nuclear AR-V7 in less than 10% of the cells (mean value of positive cells 6.4%, median 3.2%) 
(Supplementary Fig. S9a,b). In CRPC, the number of AR-V7 negative cases increased as compared to 
hormone-naïve disease (38% vs. 8% of no nuclear AR-V7 detected, respectively) (Supplementary Fig. 
S9a). Interestingly, many of the AR-V7 negative CRPC samples had a strong mesenchymal phenotype, 
while the cells in most positive tumors had round, epithelial phenotype. In the positive CRPC cases, the 
percentage of AR-V7 positive cells increased as compared to hormone-naïve disease, with mean value 
24.9% and median 13.6% (Supplementary Fig. S9b). As for the metastatic disease, 88% of the tumors 
studied had detectable AR-V7 positivity, and all 31 patients had one or more AR-V7 positive metastases. 
It should be noted that direct comparison of AR-V7 mRNA and protein levels is not possible in most of 
the cases as samples do not originate from the same tumor areas. However, general observations can be 
made. For example, patient A28 with highest AR-V7 expression at the mRNA level in the metastasis 
subjected to sequencing analysis (Fig. 1) had AR-V7 positivity in all four metastases that were studied 
with immunohistochemistry.  
 
Discussion 
 
This study describes the AR aberration status in two comprehensive patient cohorts including specimens 
from benign prostatic hyperplasia, untreated localized and metastatic prostate cancer as well as both 
locally recurrent and metastatic CRPCs. We show that even though AR-V3, AR-V7 and AR-V9 are 
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expressed widely in different sample types, they are statistically more highly expressed in metastatic 
CRPCs in comparison to two hormone-naïve sample groups, prostatectomies and lymph node metastases. 
This further reinforces the conception that AR-Vs likely have a role in CRPC progression and 
development of resistance to AR-targeted therapies.  
 
In CRPC metastases, the expression of AR-V7 was 13% of AR transcript at maximum and it was present 
in 21/29 cases whereas the expression levels of AR-V3 and AR-V9 were highly similar (7% of AR 
transcript at maximum) and detected in 23/29 and 22/29 CRPC metastases, respectively. Our finding that 
AR-V3, AR-V7 and AR-V9 are present at varying levels also in benign prostate tissue and hormone-naïve 
primary prostate cancers is in line with previous reports23,50. Furthermore, our whole genome and targeted 
DNA sequencing results were in accordance with previous reports demonstrating that AR mutations and 
amplifications are rare in early stages of untreated prostate cancer but occur much more frequently in 
patients affected by metastatic CRPC4,23,50. In our study, no AR mutations or copy number changes were 
detected in untreated cases; they were observed only in locally recurrent and metastatic CRPC specimens. 
In CRPC metastases, 5/23 cases harbored an AR mutation and 19/23 cases had a copy number gain or 
amplification. Out of 22 cases of metastatic CRPC of which both DNA- and RNA-seq data was available, 
all but one patient (patient A5) had at least one AR aberration underlining the crucial role of AR in the 
disease progression. Figure 4 summarizes both genome and RNA level alterations of AR detected in this 
study during different stages of prostate cancer. 
 
It is noteworthy that lymph node metastasis specimens from patients that had not undergone any 
androgen deprivation therapy did not show elevated levels of AR-Vs. It has been demonstrated earlier 
using several prostate cancer cell lines that inhibition of the full-length AR protein via castration, 
antiandrogen treatment or siRNA induced the expression of AR-V7, although concomitant, yet lesser 
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increases in full-length AR were also observed51,52. It has also been shown that ADT does not directly 
regulate levels of AR-V7 but rather enhances AR gene transcription rate and splicing factor recruitment 
to AR pre-mRNA thus elevating AR-V7 levels53. Accordingly, we also showed that the expression levels 
of AR-V7 as well as levels of AR-V3 and AR-V9 were strongly associated with the levels of full-length 
AR indicating that the AR-V expression is dependent on transcription rate of AR locus.  
 
Interestingly, we observed that AR-V7 was strongly co-expressed with AR-V9 in sample set 2, which is 
in line with a recent report also demonstrating simultaneous expression of AR-V7 and AR-V9 in CRPC 
metastases30. Moreover, our data showed that AR-V7 was co-expressed with AR-V3 and there was also a 
clear positive correlation between expression of AR-V9 and AR-V3. It should be noted that out of 25 
CRPC metastases that expressed any AR variant, as many as 17 cases harbored expression of all three of 
these AR-Vs. Since AR-V3, AR-V7 and AR-V9 are constitutively active, it is reasonable to expect that 
their combined contribution to prostate cancer progression might be greater than what could be expected 
when their effects are studied separately. In our data, AR-V expression levels were above 5% when 
compared to overall AR transcript expression levels in 11 metastatic CRPC specimens (sample set 2). 
Since metastatic CRPC specimens harbored three times higher expression of AR-FL in comparison to 
hormone-naïve prostatectomy samples it would mean that 5% AR-V fraction does not yet bring the AR-
V levels to corresponding levels of AR-FL in hormone-naïve prostate cancer. However, the levels of AR-
V required to drive an androgen-independent transcriptome are unknown.  
 
It has been demonstrated in several cell line studies that AR-Vs are able to induce the expression of AR-
controlled genes such as KLK3, TMPRSS2 and FKBP5 in the absence of androgens or AR-FL19,20,54,55. 
Therefore, we interrogated the levels of classical AR-regulated genes in our sample sets and calculated 
the summed z-score of five androgen responsive genes (KLK3, FKBP5, TMPRSS2, ACPP and SLC45A3). 
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There was no association between the expression levels of AR-V3, AR-V7 or AR-V9 and z-score in sample 
set 2. Likewise, no correlation was detected when KLK3 expression was compared to the expression 
levels of these AR-Vs in CRPC metastases. One explanation for this discrepancy could be the fact that 
metastatic CRPC samples expressing the highest levels of AR-Vs were taken at autopsy making it highly 
unlikely that AR-regulation was anymore classical at the late stage of the disease. In addition, it has 
previously been demonstrated that bone metastases with high AR-V levels did not show high levels of 
KLK3, KLK2, FKBP5, TMPRSS2 and NKX3-1 whereas the levels of other transcripts known to be 
positively regulated by AR were elevated (including CDK1, CYCLINA2, HSP27 and C-MYC)56. 
Therefore, it seems that the expression profile induced by AR-Vs can be context-dependent and might 
not correspond to the effects observed in cell lines.  
 
As protein expression does not always fully correlate with mRNA expression, and as the AR-Vs may 
also be regulated post-transcriptionally, it is of importance to study their expression also at the protein 
level. We assessed the expression of AR-V7 by immunohistochemistry in hormone-naïve PC, locally 
recurrent CRPC and metastatic CRPC samples. Although a third of CRPCs in this cohort were found 
negative for AR-V7 protein, the results support the view that AR-V7 expression increases during 
castration resistance, and that the protein is present in most prostate cancer metastases. It is noteworthy 
that expression of AR-V7 is highly more heterogeneous than that of AR overall. This indicates either 
differences in transcriptional expression of AR-V7 between tumor cells, or heterogeneous post-
transcriptional regulation of it within tumor cell populations.  
 
Genomic structural rearrangements (GSRs) have recently been shown to define a class of AR aberrations 
occurring at a considerable frequency in CRPC material31,34. Henzler et al. studied AR-GSRs in 30 rapid 
autopsy CRPC soft tissue metastases obtained from 15 patients and found that 10/30 metastases (6/15 
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patients) displayed at least one AR-GSR event. Instead, De Laere et al. utilized liquid biopsies from 30 
chemotherapy pretreated or chemo-naïve CRPC patients and detected at least one AR-GSR in 15/30 
patients. We observed AR-GSRs in 5/30 patients with metastatic CRPC, which is considerably less when 
compared to these prior findings. The reason for this discrepancy is unclear, but it can be at least partly 
due to the fact that there were more uncovered regions in our assay (76%–82% of AR covered) than in 
Henzler et al. assay (83–89% of AR covered). Interestingly, AR-GSRs were not detected in the context 
of AR missense mutations in both our and Henzler et al. sample cohorts31. Furthermore, in our material, 
the break fusion junctions of AR-GSRs were variable demonstrating several types of rearrangements but 
none of the AR-GSRs were associated with the expression of previously known AR-Vs. Patient A27 was 
the only one whose AR-GSR was also detected by RNA-seq and his variant allele fraction was also the 
highest being 10.9%. For other patients with AR-GSRs the variant allele fractions ranged from 2.6% to 
8.6%. In CRPC metastases, half of the AR-GSR positive patients expressed AR-Vs31 whereas all but one 
of AR-GSR positive patients who were liquid-biopsied harbored AR-V expression34. Together, these 
results demonstrate that the connection of AR-GSRs and the expression of AR-Vs is highly variable in 
different sample cohorts. It is also noteworthy that in the study of Henzler et al., the only previously 
reported variant that was associated with the presence of AR-GSRs were AR-V7 and AR-V12 (ARv567es) 
but the data from De Laere et al. showed that the majority of AR-GSR positive patients expressed multiple 
previously reported AR-Vs. AR-GSRs were restricted to CRPC specimens in both our and Henzler et al. 
data suggesting that they are yet another means of CRPC to retain AR signaling.  
 
In conclusion, the finding that AR-V expression levels increase in patients treated with androgen 
deprivation therapy might indicate that there is a clonal selection pressure on the different tumor clones 
in order to maintain functional AR signaling independent of the androgen levels. We provide evidence 
that AR-V3, AR-V7 and AR-V9 are co-expressed in metastatic CRPC highlighting the fact that targeting 
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of the AR ligand-binding domain might not be sufficient to achieve clinically relevant treatment 
responses. Consequently, inhibiting AR function via regions common to all AR-Vs is likely to provide 
additional benefit to patients with CRPC. 
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Figure 1. Combined DNA and RNA sequencing data from sample set 2 assayed by targeted SureSelect 
AR sequencing. AR mutations, copy number alterations, summed score of AR-regulated gene expression 
and AR-V expression level as a fraction of AR transcript are shown. AR-V fractions are shown as CI95 
lower bound values. Additionally, FOXA1 and SPOP mutation status is included. 
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Figure 2. The correlation between AR-FL mRNA expression and mRNA expression of (a) AR-V3, (b) 
AR-V7, (c) AR-V9, (d) all three AR-Vs combined utilizing specimens from sample set 2. The counts of 
splice junction reads indicative of AR-FL or AR-Vs are plotted in the y- and x-axis, respectively. 
Spearman’s rank correlation coefficients and p-values computed via the asymptotic t approximation are 
also shown in the figures. 
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Figure 3. The correlation between (a) AR-V7 and AR-V9 mRNA expression, (b) AR-V7 and AR-V3 mRNA 
expression and (c) AR-V9 and AR-V3 mRNA expression utilizing specimens from sample set 2. The 
counts of splice junction reads indicative of given AR-Vs are plotted in the y- and x-axis. Spearman’s 
rank correlation coefficients and p-values computed via the asymptotic t approximation are also shown 
in the figures. 
 
Figure 4. Summary of the frequency of the genome and RNA level alterations of AR during different 
stages of prostate cancer. Copy number (CN) changes of AR are presented as gains (>1 copy of AR) and 
amplifications (>2 AR copies). AR-V expression levels are divided into AR-V low (<5% of splice variant 
of AR transcript) and AR-V high (>5% of splice variant of AR transcript) groups. The data is from MiSeq 
assays for all other sample groups except for BPH and locally recurrent CRPC whose data is from HiSeq 
assays. 
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Supplementary files  
 
Supplementary Figure S1. Validation of targeted SureSelect AR splicing variant detection assay using 
cell lines and two CRPC samples. SureSelect assay performance was compared to whole transcriptome 
sequencing data from this study. AR-V expression level as a fraction of AR transcript is shown. 
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Supplementary Figure S2. Combined DNA and RNA sequencing data from sample set 1 assayed by 
whole genome and whole transcriptome sequencing. AR mutations, copy number alterations, summed 
score of AR-regulated gene expression and AR-V expression level as a fraction of AR transcript are 
shown. AR-V fractions are shown as CI95 lower bound values.  
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Supplementary Figure S3. RNA-seq read alignment visualization example of patient A17, showing split 
reads aligning to exon 3 and one of the cryptic exons CE1, CE3, CE4 and CE5. This type of reads were 
used for the relative quantification of the AR-Vs by aligning them to the AR-V signature sequence 
reference.  
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Supplementary Figure S4. The correlation between AR-FL mRNA expression and mRNA expression of 
(a) AR-V3, (b) AR-V7, (c) AR-V9, (d) all three AR-Vs combined utilizing specimens from sample set 1. 
Spearman’s rank correlation coefficients and p-values computed via the asymptotic t approximation are 
also shown in the figures. 
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Supplementary Figure S5. The association between AR signaling score and the fraction of (a) AR-V3, (b) 
AR-V7, (c) AR-V9, (d) all three AR-Vs combined utilizing specimens from sample set 2. “High” group: 
summed Z-score is above the mean of all samples. “Low” group: summed Z-score is below the mean of 
all samples.  
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Supplementary Figure S6. The correlation between normalized KLK3 expression and fraction of (a) AR-
V3, (b) AR-V7, (c) AR-V9, (d) all three AR-Vs combined utilizing specimens from sample set 2. 
Spearman’s rank correlation coefficients and p-values computed via the asymptotic t approximation are 
also shown in the figures. 
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Supplementary Figure S7. AR genomic structural rearrangement (AR-GSR) detected in metastatic CRPC 
sample from patient A27. The rearrangement resulted in a truncated variant that harbored exons 1-3 and 
half of exon 4. 
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Supplementary Figure S8. Example microscopic images of AR and AR-V7 immunohistochemistry. (a) 
22Rv1 cells known to contain high AR-V7 were used as a positive control for the stainings of AR-V7 
(left panel) and AR (right panel). (b) Three representative tumors with different staining patterns are 
shown for samples of hormone-naïve PC, locally recurrent CRPC and CRPC metastases with AR-V7 
(upper panels) and AR (lower panels). Scale bars 50 m (a) and 100 m (b). 
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Supplementary Figure S9. Results of AR-V7 immunohistochemistry in hormone-naïve PC and locally 
recurrent CRPC. (a) Percentage of cases with no AR-V7 positive cells (negative) and cases with AR-V7 
positive tumor cells below or above 10% of all tumor cells. (b) Percentage of AR-V7 positive tumor cells 
within the positive samples in (a). 
 
Supplementary Table S1. Clinicopathological characteristics of the prostate cancer cases and treatments of CRPC 
cases from sample set 1 and 2. Detailed treatment modalities are shown for metastatic CRPC patients that harbored 
AR mutations.



Supplementary Table S2. Unique splice junctions for AR-V detection. 
AR-V Detected splice junction 
AR-V3 exon 2 – CE4 
AR-V4 exon 3 – CE4 
AR-V5 exon 3 – CE2-1* 
AR-V6 exon 3 – CE2-2* 
AR-V7 exon 3 – CE3 
AR-V9 exon 3 – CE5 
AR-V12 exon 4 – exon 8 
*Alternative 5’ splicing site 
 
AR-V3
Prostatectomy Lymph node metastases
Prostatectomy
Lymph node metastases 0,2947
CRPC metastases 0.0019** 0.0302*
Supplementary Table S3. Statistical comparison of individual AR variants in different sample types from sample set 2 
using two-tailed, unpaired Mann-Whitney U test.
AR-V7
Prostatectomy Lymph node metastases
Prostatectomy
Lymph node metastases 0,7458
CRPC metastases 0.0054** 0,2372
AR-V9
Prostatectomy Lymph node metastases
Prostatectomy
Lymph node metastases 0,3532
CRPC metastases 0.0007*** 0.0201*
PATIENT ID
MUTATION 
NAME CHROM POSITION REF ALT FUNCTION EXONIC_FUNCTION AA_CHANGE READS VAF
A2 AR: L702H chrX 66931463 T A exonic nonsynonymous SNV AR:NM_000044:exon4:c.T2105A:p.L702H,AR:NM_001011645:exon4:c.T509A:p.L170H74:169 0,44
A21 AR: L702H chrX 66931463 T A exonic nonsynonymous SNV AR:NM_000044:exon4:c.T2105A:p.L702H,AR:NM_001011645:exon4:c.T509A:p.L170H7:975 0,06
A33 AR: L702H chrX 66931463 T A exonic nonsynonymous SNV AR:NM_000044:exon4:c.T2105A:p.L702H,AR:NM_001011645:exon4:c.T509A:p.L170H47:180 0,26
A22 AR: T878A chrX 66943552 A G exonic nonsynonymous SNV AR:NM_000044:exon8:c.A2632G:p.T878A,AR:NM_001011645:exon8:c.A1036G:p.T346A27:146 0,18
A24 AR: T878A chrX 66943552 A G exonic nonsynonymous SNV AR:NM_000044:exon8:c.A2632G:p.T878A,AR:NM_001011645:exon8:c.A1036G:p.T346A564:578 0,98
PB50 FOXA1: G39R chr14 38061874 C G exonic nonsynonymous SNV FOXA1:NM_004496:exon2:c.G115C:p.G39R44:270 0,16
PB283 FOXA1: S250F chr14 38061240 G A exonic nonsynonymous SNV FOXA1:NM_004496:exon2:c.C749T:p.S250F83:265 ,31
A16 FOXA1: R265H chr14 38061195 C T exonic nonsynonymous SNV FOXA1:NM_004496:exon2:c.G794A:p.R265H80:139 0,58
PB273 FOXA1: R447fs chr14 38060648 C - exonic frameshift deletion FOXA1:NM_004496:exon2:c.1341delG:p.R447fs97:250 0,39
A21 SPOP: F102C chr17 47696643 A C exonic nonsynonymous SNV SPOP:NM_001007228:exon4:c.T305G:p.F102C,SPOP:NM_001007227:exon5:c.T305G:p.F102C,SPOP:NM_001007229:exon5:c.T305G:p.F102C,SPOP:NM_003563:exon5:c.T305G:p.F102C,SPOP:NM_001007226:exon6:c.T305G:p.F102C,SPOP:NM_001007230:exon6:c.T305G:p.F102C108:252 0,43
PB142 SPOP: F102C chr17 47696643 A C exonic nonsynonymous SNV SPOP:NM_001007228:exon4:c.T305G:p.F102C,SPOP:NM_001007227:exon5:c.T305G:p.F102C,SPOP:NM_001007229:exon5:c.T305G:p.F102C,SPOP:NM_003563:exon5:c.T305G:p.F102C,SPOP:NM_001007226:exon6:c.T305G:p.F102C,SPOP:NM_001007230:exon6:c.T305G:p.F102C162: 58 0,45
A33 SPOP: F133V chr17 47696426 A C exonic nonsynonymous SNV SPOP:NM_001007228:exon5:c.T397G:p.F133V,SPOP:NM_001007227:exon6:c.T397G:p.F133V,SPOP:NM_001007229:exon6:c.T397G:p.F133V,SPOP:NM_003563:exon6:c.T397G:p.F133V,SPOP:NM_001007226:exon7:c.T397G:p.F133V,SPOP:NM_001007230:exon7:c.T397G:p.F133V74:210 0, 5
Supplementary Table 5. AR genomic structural rearrangements detected in metastatic CRPC 
specimens. 
 
Patient 
ID 
AR 
copy 
number 
 
Tumour 
type 
 
Tissue 
 
AR-GSR 
Break fusion 
junction 
coordinates 
(hg19) 
 
Remarks 
# 
supporting 
split reads 
Variant 
allele 
fraction 
 
 
 
A4 
 
 
 
68 
 
 
 
CRPC 
metastasis 
 
 
 
Liver 
 
 
 
Inversion 
 
 
chrX:66,189,781 / 
chrX:66,863,033 
5’ breakpoint located 
in a LINE-1 element 
between EDA2R and 
AR, region containing 
exon 1, 1b and most 
of intron 1 inverted 
 
 
 
22 
 
 
 
8.6% 
 
A7 
 
6 
 
CRPC 
metastasis 
 
Subdural 
 
Inversion 
 
chrX:66,783,645 / 
chrX:66,784,142 
Inverted ~500bp 
region in AR intron 1 
between exon 1 and 
1b 
 
53 
 
5.4% 
 
 
 
A8 
 
 
 
59 
 
 
 
CRPC 
metastasis 
 
 
 
Liver 
 
 
 
Translocation 
 
 
chr7:35,711,637 / 
chrX:66,911,250 
5’ breakpoint located 
in a LINE-1 element 
in HERPUD2 intron 
3, 3’ breakpoint in AR 
intron 3  -> deletion 
of cryptic exons 
CE3/CE5 + exons 4-8 
 
 
 
18 
 
 
 
2.6% 
 
A11 
 
7 
 
CRPC 
metastasis 
 
Inguinal 
lymph 
node 
 
Duplication 
 
chrX:116,819,638 
/ chrX:66,769,235 
 
AR intron 1 
breakpoint between 
exons 1 and 1b (exon 
1 deleted) 
 
32 
 
6.2% 
 
A27 
 
9 
 
CRPC 
metastasis 
 
Axillary 
lymph 
node 
 
Deletion 
 
chrX:66,931,389 / 
chrX:66,942,180 
Deletes half of exon 4 
+ exons 5 and 6; 
detected also from 
RNA-seq sample 
 
37 
 
10.9% 
Supplementary Table S4. AR, FOXA1 and SPOP mutations detected in sample set 2.
